Showing results (221-230 of 249) with videos related to

Sort By:
Pageof 25
British Journal of Cancer|August 23, 2012
Vascular density analysis in colorectal cancer patients treated with vatalanib (PTK787/ZK222584) in the randomised CONFIRM trialsA Giatromanolaki, M I Koukourakis, E Sivridis, et al.
Zeitschrift Fur Gastroenterologie|November 24, 2004
[Consensus-recommendations for sirolimus in liver transplantation]M Golling, T Becker, C Broelsch, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 7, 2018
Impact of age on the efficacy of oxaliplatin in the preoperative chemoradiotherapy and adjuvant chemotherapy of rectal cancer: a post hoc analysis of the CAO/ARO/AIO-04 phase III trialR-D Hofheinz, D Arnold, E Fokas, et al.
Transplantation|June 27, 1997
A prospective randomized trial comparing interleukin-2 receptor antibody versus antithymocyte globulin as part of a quadruple immunosuppressive induction therapy following orthotopic liver transplantationJ M Langrehr, N C Nüssler, U Neumann, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 16, 2013
Regorafenib in combination with FOLFOX or FOLFIRI as first- or second-line treatment of colorectal cancer: results of a multicenter, phase Ib studyB Schultheis, G Folprecht, J Kuhlmann, et al.
BMC Cancer|October 24, 2019
Consensus in determining the resectability of locally progressed pancreatic ductal adenocarcinoma - results of the Conko-007 multicenter trialU A Wittel, D Lubgan, M Ghadimi, et al.
ESMO Open|September 5, 2021
A randomized phase II study comparing the efficacy and safety of the glyco-optimized anti-EGFR antibody tomuzotuximab against cetuximab in patients with recurrent and/or metastatic squamous cell cancer of the head and neck - the RESGEX studyK Klinghammer, J Fayette, A Kawecki, et al.
The Pharmacogenomics Journal|June 6, 2012
Intratumoral expression profiling of genes involved in angiogenesis in colorectal cancer patients treated with chemotherapy plus the VEGFR inhibitor PTK787/ZK 222584 (vatalanib)P M Wilson, D Yang, M Azuma, et al.
ESMO Open|July 24, 2025
Durvalumab and tremelimumab plus local partial tumour ablation (radiofrequency ablation or stereotactic radiotherapy) in patients with unresectable liver metastases from metastatic colorectal cancer: results of the EORTC-1560-GITCG multicentre, single-arm phase II study (ILOC)J Seligmann, T Koessler, M Mauer, et al.
European Journal of Cancer (Oxford, England : 1990)|December 2, 2017
Surgical treatment options following chemotherapy plus cetuximab or bevacizumab in metastatic colorectal cancer-central evaluation of FIRE-3D P Modest, T Denecke, J Pratschke, et al.
Pageof 25